Comparison of different estimated glomerular filtration rates for monitoring of kidney function in oncology patients.

cystatin C glomerular filtration rate estimation kidney function renal cell carcinoma tyrosine kinase inhibitors

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 17 10 2023
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 30 1 2024
Statut: epublish

Résumé

Tyrosine kinase inhibitors (TKIs) are associated with kidney function deterioration. A shift is ongoing towards glomerular filtration rate (GFR) equations based on other protein markers, such as cystatin C (CSTC) and β-trace protein (BTP). We evaluated various GFR equations for monitoring of kidney function in actively treated oncology patients. We monitored 110 patients receiving a TKI. Blood and urine were collected during therapy. Serum analysis included creatinine (Cr), CSTC and BTP; for consequent GFR determination. Urine was analysed for protein, albumin, immunoglobulin G, and α-1-microglobulin. A similar analysis was done in a patient subgroup receiving immune checkpoint inhibitors (ICI) as prior or subsequent line of therapy. Cr remained constant during TKI treatment ( GFR equations, in which CSTC is incorporated, fail to correctly estimate the GFR in oncology patients treated with TKIs. As TKI-treated patients show clear signs of glomerular injury, further assessment is needed on how to correctly monitor the kidney function in actively treated oncology patients.

Sections du résumé

Background UNASSIGNED
Tyrosine kinase inhibitors (TKIs) are associated with kidney function deterioration. A shift is ongoing towards glomerular filtration rate (GFR) equations based on other protein markers, such as cystatin C (CSTC) and β-trace protein (BTP). We evaluated various GFR equations for monitoring of kidney function in actively treated oncology patients.
Methods UNASSIGNED
We monitored 110 patients receiving a TKI. Blood and urine were collected during therapy. Serum analysis included creatinine (Cr), CSTC and BTP; for consequent GFR determination. Urine was analysed for protein, albumin, immunoglobulin G, and α-1-microglobulin. A similar analysis was done in a patient subgroup receiving immune checkpoint inhibitors (ICI) as prior or subsequent line of therapy.
Results UNASSIGNED
Cr remained constant during TKI treatment (
Conclusion UNASSIGNED
GFR equations, in which CSTC is incorporated, fail to correctly estimate the GFR in oncology patients treated with TKIs. As TKI-treated patients show clear signs of glomerular injury, further assessment is needed on how to correctly monitor the kidney function in actively treated oncology patients.

Identifiants

pubmed: 38288036
doi: 10.1093/ckj/sfae006
pii: sfae006
pmc: PMC10823486
doi:

Types de publication

Journal Article

Langues

eng

Pagination

sfae006

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

Déclaration de conflit d'intérêts

T.V. has received support for attending meetings and/or travel from MSD Belgium within the past 36 months. N.L. has received Grants from Bayer, Ipsen, and Janssen within the past 36 months.

Auteurs

Tijl Vermassen (T)

Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
Biomarkers in Cancer, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent, Ghent, Belgium.

Karen Geboes (K)

Cancer Research Institute Ghent, Ghent, Belgium.
Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.

Nicolaas Lumen (N)

Cancer Research Institute Ghent, Ghent, Belgium.
Department of Urology, University Hospital Ghent, Ghent, Belgium.
Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

Charles Van Praet (C)

Cancer Research Institute Ghent, Ghent, Belgium.
Department of Urology, University Hospital Ghent, Ghent, Belgium.
Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

Sylvie Rottey (S)

Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
Biomarkers in Cancer, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent, Ghent, Belgium.
Drug Research Unit Ghent, University Hospital Ghent, Ghent, Belgium.

Joris Delanghe (J)

Cancer Research Institute Ghent, Ghent, Belgium.
Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.

Classifications MeSH